Radical surgery is highlighted as the best treatment for pancreatic cancer, with FOLFIRINOX showing promise in chemotherapy for advanced cases. Post-surgery, microscopic disease often remains, requiring a multidisciplinary approach. Neoadjuvant therapy needs precise disease staging, while neuroendocrine tumours benefit from dual imaging. Gallbladder cancer often presents late, complicating treatment. Intrahepatic cholangiocarcinoma and hepatocellular cancer require careful patient selection and are seeing advancements with immune checkpoint inhibitors.